AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: tumors

newssourceFORcompanyinformationcontent1releasesmarket

Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2025, and provide a corporate update on August 14, 2025, at 8:30 a.m. Eastern Time.

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of 2025 Initiated ALKAZAR...

US NCI Sponsors Senhwa Biosciences’ Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight

The dynamics of the urothelial carcinoma market are anticipated to change due to the demand for innovative therapies, particularly in chemotherapy and immunotherapy, and...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

CLK Inhibitors Market Poised for Growth as Demand Rises in Oncology and Musculoskeletal Disorders | DelveInsight

The CLK inhibitors market is projected to expand in the coming years, driven by a rising incidence of cancer diagnoses, growing awareness of these...

Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeyso™ (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma

Modeyso is the first treatment option for this ultra-rare and aggressive brain tumor, which primarily affects children and young adults Accelerated approval based on an...

Intas Pharmaceuticals Launches HETRONIFLY™ (Serplulimab), India’s First Novel Immunotherapy for Advanced Small Cell Lung Cancer

AHMEDABAD, India, Aug. 5, 2025 /PRNewswire/ -- Intas Pharmaceuticals has launched HETRONIFLY™ (Serplulimab), the first PD-1 inhibitor globally approved for the treatment of Extensive-Stage...

Hemispherian Receives FDA IND Clearance for First-in-Class Glioblastoma Therapeutic, GLIX1

OSLO, Norway, Aug. 5, 2025 /PRNewswire/ -- Hemispherian AS, a pioneering biotech company developing next-generation therapeutics for aggressive cancers, today announced that the U.S....

CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

         - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis -

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m. EDT (2:00 p.m. CEST)

Alphamab Oncology Announces IND Application for Innovative PD-L1/αvβ6 Bispecific ADC JSKN022 was Officially Accepted by CDE

SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently...

2025 Pan-Mass Challenge Draws Thousands of Cyclists to Fuel Next Era of Cancer Research

World's most successful athletic fundraiser aims to raise record $76 million BOSTON, Aug. 2, 2025 /PRNewswire/ -- This weekend, the Pan-Mass Challenge (PMC) unites more than...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTumors

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers